PL2528627T3 - Radioimmunokoniugaty i ich zastosowania - Google Patents

Radioimmunokoniugaty i ich zastosowania

Info

Publication number
PL2528627T3
PL2528627T3 PL11700972T PL11700972T PL2528627T3 PL 2528627 T3 PL2528627 T3 PL 2528627T3 PL 11700972 T PL11700972 T PL 11700972T PL 11700972 T PL11700972 T PL 11700972T PL 2528627 T3 PL2528627 T3 PL 2528627T3
Authority
PL
Poland
Prior art keywords
radioimmunoconjugates
Prior art date
Application number
PL11700972T
Other languages
English (en)
Inventor
Roy H Larsen
Jostein Dahle
Øyvind S Bruland
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of PL2528627T3 publication Critical patent/PL2528627T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11700972T 2010-01-29 2011-01-28 Radioimmunokoniugaty i ich zastosowania PL2528627T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
EP11700972.0A EP2528627B1 (en) 2010-01-29 2011-01-28 Radioimmunoconjugates and uses thereof
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
PL2528627T3 true PL2528627T3 (pl) 2014-08-29

Family

ID=44319900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11700972T PL2528627T3 (pl) 2010-01-29 2011-01-28 Radioimmunokoniugaty i ich zastosowania

Country Status (26)

Country Link
US (2) US8628749B2 (pl)
EP (2) EP2528627B1 (pl)
JP (2) JP5646652B2 (pl)
KR (2) KR101893720B1 (pl)
CN (2) CN102762230B (pl)
AU (1) AU2011209441B2 (pl)
BR (1) BR112012018843B8 (pl)
CA (1) CA2786655C (pl)
DK (2) DK2528627T3 (pl)
ES (2) ES2469140T3 (pl)
HK (2) HK1179157A1 (pl)
HR (1) HRP20140538T1 (pl)
IL (2) IL221091A (pl)
MX (2) MX2012008695A (pl)
NO (1) NO331080B1 (pl)
NZ (1) NZ601055A (pl)
PH (1) PH12017501038A1 (pl)
PL (1) PL2528627T3 (pl)
PT (1) PT2528627E (pl)
RS (1) RS53346B (pl)
RU (2) RU2664475C1 (pl)
SG (1) SG182685A1 (pl)
SI (1) SI2528627T1 (pl)
UA (1) UA108631C2 (pl)
WO (1) WO2011092295A2 (pl)
ZA (1) ZA201205007B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088363A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
SG11201405766SA (en) * 2012-03-30 2014-10-30 Immunogen Inc Methods for increasing efficacy of cd37-based therapy
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
CN105451781B (zh) * 2013-06-07 2018-07-27 诺帝克纳诺维科特公司 用于上调抗原表达的方法
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
CN107735110B (zh) * 2015-04-07 2021-11-26 纪念斯隆-凯特琳癌症中心 纳米粒子免疫偶联物
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
EP3512881A1 (en) * 2016-09-16 2019-07-24 Nordic Nanovector ASA Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
KR20030016250A (ko) * 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 중추신경계 림프종 치료용 리툭시맵의 초내 투여
EP1569690B1 (en) * 2002-12-13 2011-07-27 Mitra Medical Technology AB Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004213752B2 (en) * 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US7259249B2 (en) * 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
MX342539B (es) 2016-10-04
AU2011209441B2 (en) 2016-03-03
AU2011209441A1 (en) 2012-07-19
NO20100143A1 (no) 2011-08-01
DK2528627T3 (da) 2014-05-12
UA108631C2 (xx) 2015-05-25
EP2705857B1 (en) 2016-06-22
PH12017501038B1 (en) 2017-12-11
NO331080B1 (no) 2011-09-26
EP2528627B1 (en) 2014-03-19
RU2012135430A (ru) 2014-03-10
JP5646652B2 (ja) 2014-12-24
BR112012018843A2 (pt) 2017-10-17
JP5855209B2 (ja) 2016-02-09
BR112012018843B1 (pt) 2020-09-24
JP2015057415A (ja) 2015-03-26
KR20170084349A (ko) 2017-07-19
CN102762230B (zh) 2014-08-13
PH12017501038A1 (en) 2017-12-11
CA2786655A1 (en) 2011-08-04
MX2012008695A (es) 2012-11-23
SI2528627T1 (sl) 2014-08-29
US9358309B2 (en) 2016-06-07
RS53346B (en) 2014-10-31
WO2011092295A3 (en) 2011-11-24
EP2528627A2 (en) 2012-12-05
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
US8628749B2 (en) 2014-01-14
RU2560587C9 (ru) 2015-11-27
BR112012018843B8 (pt) 2020-12-22
WO2011092295A2 (en) 2011-08-04
KR20130028051A (ko) 2013-03-18
CN102762230A (zh) 2012-10-31
ZA201205007B (en) 2013-09-25
IL221091A (en) 2015-03-31
DK2705857T3 (en) 2016-08-29
KR101758409B1 (ko) 2017-07-14
IL237507A0 (en) 2015-04-30
CN104338154A (zh) 2015-02-11
PT2528627E (pt) 2014-06-12
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
US20140147384A1 (en) 2014-05-29
HRP20140538T1 (hr) 2014-07-18
IL221091A0 (en) 2012-09-24
CN104338154B (zh) 2017-09-22
JP2013518086A (ja) 2013-05-20
ES2592402T3 (es) 2016-11-30
HK1179157A1 (en) 2013-09-27
ES2469140T3 (es) 2014-06-17
CA2786655C (en) 2016-12-13
EP2705857A2 (en) 2014-03-12
KR101893720B1 (ko) 2018-08-30
EP2705857A3 (en) 2014-07-30
US20120301396A1 (en) 2012-11-29
BR112012018843A8 (pt) 2017-12-19
HK1195736A1 (zh) 2014-11-21

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
IL237507A0 (en) Radioimmunoconjugates and their uses
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
HRP20182083T1 (hr) Nova kombinacija i uporaba
AP2013006947A0 (en) Compounds and their use
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201014319D0 (en) Compounds and uses thereof
GB201020268D0 (en) Composition and uses
EP2567956A4 (en) NEW PRENYLAR CONNECTION AND USE THEREOF